Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Core Insights - Phio Pharmaceuticals is set to present clinical data from its ongoing Phase 1b trial of siRNA-based INTASYL PH-762 for skin cancer at the 40th Annual Meeting of the Society for Immunotherapy of Cancer [1][2] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at eliminating cancer [1][4] - The company's lead clinical program, PH-762, targets the PD-1 gene, which is implicated in various forms of skin cancer, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] Clinical Trial Details - The ongoing Phase 1b clinical trial is designed to evaluate the safety and tolerability of intratumoral injection of PH-762 in patients with specific skin cancers [2][4] - The trial is registered under NCT 06014086 and aims to assess PH-762 as a potential non-surgical treatment option for skin cancers [4] Presentation Information - The poster presentation titled "PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: A Clinical Study of INTASYL PH-762" will be presented by Mary Spellman, M.D. on November 8, 2025 [3]